Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women

Andrea Ries Thurman, Nazita Yousefieh, Neelima Chandra, Thomas Kimble, Susana Asin, Christiane Rollenhagen, Sharon M. Anderson, Betsy Herold, Jamie L. Freiermuth, Brian S. Starkman, Pedro M.M. Mesquita, Nicola Richardson-Harman, Tina Cunningham, Sharon Hillier, Lorna Rabe, Jill L. Schwartz, Gustavo F. Doncel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The objective of this study was to characterize cervicovaginal (CV) mucosal factors modulating susceptibility to human immunodeficiency virus (HIV) acquisition in healthy premenopausal (PRE) and postmenopausal (POST) women before and after treatment with estradiol (E2). We compared CV mucosal epithelial histology and immune cells, vaginal microbiota, antimicrobial activity of and soluble mucosal protein concentrations in the CV fluid lavage (CVL), and p24 antigen production after ex vivo infection of ectocervical tissues with HIV-1BaL among PRE women (n = 20) in the follicular and luteal phases of the menstrual cycle and POST women (n = 17) at baseline and after ∼1 month of treatment with 0.01% vaginal E2 cream. Compared to PRE women, we measured higher levels of p24 antigen after ex viv infection in tissues from POST women. POST women had a significantly thinner vaginal epithelium with decreased tight junction proteins and a higher density of mucosal immune T cells and lower levels of CD1a antigen-presenting cells, antimicrobial peptides, and inflammatory cytokines in the CVL (p values <.05). POST women had higher vaginal pH and lower vaginal Lactobacilli (p values <.05) than PRE women. After vaginal E2 therapy, CV endpoints and ex vivo HIV replication in POST tissues were similar to those observed in PRE tissues. The CV mucosa in POST women is thinned and compromised, with increased HIV-target immune cells and decreased antimicrobial factors, being more susceptible to HIV infection. After POST women receive topical E2 treatment, mucosal endpoints are similar to PRE levels.

Original languageEnglish (US)
Pages (from-to)807-819
Number of pages13
JournalAIDS Research and Human Retroviruses
Volume33
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

HIV
Therapeutic Irrigation
Foams and Jellies Vaginal Creams
Tight Junction Proteins
Antigens
Follicular Phase
Luteal Phase
Microbiota
Lactobacillus
Antigen-Presenting Cells
Virus Diseases
Therapeutics
Virus Replication
Infection
Estradiol
Histology
Mucous Membrane
Epithelium
Cytokines
T-Lymphocytes

Keywords

  • cervicovaginal
  • HIV
  • hormones
  • menopause
  • mucosal

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women. / Thurman, Andrea Ries; Yousefieh, Nazita; Chandra, Neelima; Kimble, Thomas; Asin, Susana; Rollenhagen, Christiane; Anderson, Sharon M.; Herold, Betsy; Freiermuth, Jamie L.; Starkman, Brian S.; Mesquita, Pedro M.M.; Richardson-Harman, Nicola; Cunningham, Tina; Hillier, Sharon; Rabe, Lorna; Schwartz, Jill L.; Doncel, Gustavo F.

In: AIDS Research and Human Retroviruses, Vol. 33, No. 8, 01.08.2017, p. 807-819.

Research output: Contribution to journalArticle

Thurman, AR, Yousefieh, N, Chandra, N, Kimble, T, Asin, S, Rollenhagen, C, Anderson, SM, Herold, B, Freiermuth, JL, Starkman, BS, Mesquita, PMM, Richardson-Harman, N, Cunningham, T, Hillier, S, Rabe, L, Schwartz, JL & Doncel, GF 2017, 'Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women', AIDS Research and Human Retroviruses, vol. 33, no. 8, pp. 807-819. https://doi.org/10.1089/aid.2016.0320
Thurman, Andrea Ries ; Yousefieh, Nazita ; Chandra, Neelima ; Kimble, Thomas ; Asin, Susana ; Rollenhagen, Christiane ; Anderson, Sharon M. ; Herold, Betsy ; Freiermuth, Jamie L. ; Starkman, Brian S. ; Mesquita, Pedro M.M. ; Richardson-Harman, Nicola ; Cunningham, Tina ; Hillier, Sharon ; Rabe, Lorna ; Schwartz, Jill L. ; Doncel, Gustavo F. / Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women. In: AIDS Research and Human Retroviruses. 2017 ; Vol. 33, No. 8. pp. 807-819.
@article{689b43f5b1fb4eaca38a19ebe8ceed99,
title = "Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women",
abstract = "The objective of this study was to characterize cervicovaginal (CV) mucosal factors modulating susceptibility to human immunodeficiency virus (HIV) acquisition in healthy premenopausal (PRE) and postmenopausal (POST) women before and after treatment with estradiol (E2). We compared CV mucosal epithelial histology and immune cells, vaginal microbiota, antimicrobial activity of and soluble mucosal protein concentrations in the CV fluid lavage (CVL), and p24 antigen production after ex vivo infection of ectocervical tissues with HIV-1BaL among PRE women (n = 20) in the follicular and luteal phases of the menstrual cycle and POST women (n = 17) at baseline and after ∼1 month of treatment with 0.01{\%} vaginal E2 cream. Compared to PRE women, we measured higher levels of p24 antigen after ex viv infection in tissues from POST women. POST women had a significantly thinner vaginal epithelium with decreased tight junction proteins and a higher density of mucosal immune T cells and lower levels of CD1a antigen-presenting cells, antimicrobial peptides, and inflammatory cytokines in the CVL (p values <.05). POST women had higher vaginal pH and lower vaginal Lactobacilli (p values <.05) than PRE women. After vaginal E2 therapy, CV endpoints and ex vivo HIV replication in POST tissues were similar to those observed in PRE tissues. The CV mucosa in POST women is thinned and compromised, with increased HIV-target immune cells and decreased antimicrobial factors, being more susceptible to HIV infection. After POST women receive topical E2 treatment, mucosal endpoints are similar to PRE levels.",
keywords = "cervicovaginal, HIV, hormones, menopause, mucosal",
author = "Thurman, {Andrea Ries} and Nazita Yousefieh and Neelima Chandra and Thomas Kimble and Susana Asin and Christiane Rollenhagen and Anderson, {Sharon M.} and Betsy Herold and Freiermuth, {Jamie L.} and Starkman, {Brian S.} and Mesquita, {Pedro M.M.} and Nicola Richardson-Harman and Tina Cunningham and Sharon Hillier and Lorna Rabe and Schwartz, {Jill L.} and Doncel, {Gustavo F.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1089/aid.2016.0320",
language = "English (US)",
volume = "33",
pages = "807--819",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women

AU - Thurman, Andrea Ries

AU - Yousefieh, Nazita

AU - Chandra, Neelima

AU - Kimble, Thomas

AU - Asin, Susana

AU - Rollenhagen, Christiane

AU - Anderson, Sharon M.

AU - Herold, Betsy

AU - Freiermuth, Jamie L.

AU - Starkman, Brian S.

AU - Mesquita, Pedro M.M.

AU - Richardson-Harman, Nicola

AU - Cunningham, Tina

AU - Hillier, Sharon

AU - Rabe, Lorna

AU - Schwartz, Jill L.

AU - Doncel, Gustavo F.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The objective of this study was to characterize cervicovaginal (CV) mucosal factors modulating susceptibility to human immunodeficiency virus (HIV) acquisition in healthy premenopausal (PRE) and postmenopausal (POST) women before and after treatment with estradiol (E2). We compared CV mucosal epithelial histology and immune cells, vaginal microbiota, antimicrobial activity of and soluble mucosal protein concentrations in the CV fluid lavage (CVL), and p24 antigen production after ex vivo infection of ectocervical tissues with HIV-1BaL among PRE women (n = 20) in the follicular and luteal phases of the menstrual cycle and POST women (n = 17) at baseline and after ∼1 month of treatment with 0.01% vaginal E2 cream. Compared to PRE women, we measured higher levels of p24 antigen after ex viv infection in tissues from POST women. POST women had a significantly thinner vaginal epithelium with decreased tight junction proteins and a higher density of mucosal immune T cells and lower levels of CD1a antigen-presenting cells, antimicrobial peptides, and inflammatory cytokines in the CVL (p values <.05). POST women had higher vaginal pH and lower vaginal Lactobacilli (p values <.05) than PRE women. After vaginal E2 therapy, CV endpoints and ex vivo HIV replication in POST tissues were similar to those observed in PRE tissues. The CV mucosa in POST women is thinned and compromised, with increased HIV-target immune cells and decreased antimicrobial factors, being more susceptible to HIV infection. After POST women receive topical E2 treatment, mucosal endpoints are similar to PRE levels.

AB - The objective of this study was to characterize cervicovaginal (CV) mucosal factors modulating susceptibility to human immunodeficiency virus (HIV) acquisition in healthy premenopausal (PRE) and postmenopausal (POST) women before and after treatment with estradiol (E2). We compared CV mucosal epithelial histology and immune cells, vaginal microbiota, antimicrobial activity of and soluble mucosal protein concentrations in the CV fluid lavage (CVL), and p24 antigen production after ex vivo infection of ectocervical tissues with HIV-1BaL among PRE women (n = 20) in the follicular and luteal phases of the menstrual cycle and POST women (n = 17) at baseline and after ∼1 month of treatment with 0.01% vaginal E2 cream. Compared to PRE women, we measured higher levels of p24 antigen after ex viv infection in tissues from POST women. POST women had a significantly thinner vaginal epithelium with decreased tight junction proteins and a higher density of mucosal immune T cells and lower levels of CD1a antigen-presenting cells, antimicrobial peptides, and inflammatory cytokines in the CVL (p values <.05). POST women had higher vaginal pH and lower vaginal Lactobacilli (p values <.05) than PRE women. After vaginal E2 therapy, CV endpoints and ex vivo HIV replication in POST tissues were similar to those observed in PRE tissues. The CV mucosa in POST women is thinned and compromised, with increased HIV-target immune cells and decreased antimicrobial factors, being more susceptible to HIV infection. After POST women receive topical E2 treatment, mucosal endpoints are similar to PRE levels.

KW - cervicovaginal

KW - HIV

KW - hormones

KW - menopause

KW - mucosal

UR - http://www.scopus.com/inward/record.url?scp=85027014361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027014361&partnerID=8YFLogxK

U2 - 10.1089/aid.2016.0320

DO - 10.1089/aid.2016.0320

M3 - Article

C2 - 28398069

AN - SCOPUS:85027014361

VL - 33

SP - 807

EP - 819

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 8

ER -